Nimotuzumab in the Treatment of Severe Pneumonia due to COVID-19. Presentation of a Case

Authors: Pedroso RM*

DOI: 10.23880/pdraj-16000145

Volume 6, Issue 1

Abstract

Introduction: Severe pneumonia due to COVID-19 has a high mortality, one of the therapeutic alternatives may be Nimotuzumab. Objective: To describe the clinical, humoral and radiological evolution of a patient with severe pneumonia due to COVID-19. Case Presentation: 77-year-old female patient with a history of Bronchial Asthma and COPD, psychiatric disorders who develops severe pneumonia (RALE 4 points) in the course of SARS-Cov-2 infection and after medical treatment with the Nimotuzumab monoclonal antibody is recovered. Symptoms, complementary and radiographs are shown before and after medical treatment. Conclusions: Nimotuzumab can be a therapeutic alternative in patients admitted to intensive care affected with moderate and severe pneumonia due to COVID-19.

Keywords: Pneumonia; COVID-19; Symptoms; Nimotuzumab

View PDF